Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

PURPOSE: The purpose of this study was to compare the efficacy and safety of brexpiprazole 4 mg/day (B4) and 2 mg/day (B2) for treating acute schizophrenia. PATIENTS AND METHODS: We performed three categorical meta-analyses (B4 vs placebo, B2 vs placebo, and B4 vs B2) of double-blind, randomized pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Oya, Kazuto, Matsui, Yuki, Nomura, Ikuo, Sakuma, Kenji, Okuya, Makoto, Matsuda, Yuki, Fujita, Kiyoshi, Funahashi, Toshihiko, Yoshimura, Reiji, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171755/
https://www.ncbi.nlm.nih.gov/pubmed/30319261
http://dx.doi.org/10.2147/NDT.S176676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171755/
https://www.ncbi.nlm.nih.gov/pubmed/30319261
http://dx.doi.org/10.2147/NDT.S176676

Ejemplares similares